Atomoxetine Treatment Outcomes in Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: Results From a Post Hoc, Pooled Analysis

Clinical Therapeutics

Volumn 34, Issue 2, 2012, Pages 363-373

  Adler, Lenard A ^a,b   Wilens, Timothy ^c   Zhang, Shuyu ^d   Dittmann, Ralf W ^e   D'Souza, Deborah N ^f   Schuh, Leslie ^g   Durell, Todd M ^h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Veterans Health Administration Harbor Healthcare System   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^f SYNEOS HEALTH   (United States)

^g St Vincent Bariatric Center of Excellence   (United States)

^h Lilly USA   (United States)

Author keywords

ADHD; Adolescence; Atomoxetine; Young adulthood

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; POOLED ANALYSIS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SORE THROAT; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; HUMANS; MALE; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863028212     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.12.015     Document Type: Article

References (28)

1. Froehlich T.E., Lanphear B.P., Epstein J.N., et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007, 161:857-864.
2. Wolf L.E. College students with ADHD and other hidden disabilities. Outcomes and interventions. Ann N Y Acad Sci 2001, 931:385-395.
3. Barkley R.A., Murphy K.R., Bush T. Time perception and reproduction in young adults with attention deficit hyperactivity disorder. Neuropsychology 2001, 15:351-360.
4. Barkley R.A., Anastopoulos A.D., Guevremont D.C., Fletcher K.E. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization. J Am Acad Child Adolesc Psychiatry 1991, 30:752-761.
5. Clinicians Guide to Adult ADHD: Assessment and Intervention 2002, Academic Press, New York, NY. S. Goldstein, A.T. Ellison (Eds.).
6. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163:716-723.
7. Wolraich M.L., Wibbelsman C.J., Brown T.E., et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005, 115:1734-1746.
8. Biederman J., Wilens T., Mick E., et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999, 104:e20.
9. Wilens T.E., Adler L.A., Adams J., et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47:21-31.
10. Vaughan B., Fegert J., Kratochvil C.J. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2009, 10:669-676.
11. McCabe S.E., Teter C.J., Boyd C.J. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs 2006, 38:43-56.
12. Wilens T.E., Kratochvil C., Newcorn J.H., Gao H. Do children and adolescents with ADHD respond differently to atomoxetine?. J Am Acad Child Adolesc Psychiatry 2006, 45:149-157.
13. Durell T., Adler L., Wilens T., et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord 2010, 13:401-406.
14. Piatigorsky A., Hinshaw S.P. Psychopathic traits in boys with and without attention-deficit/hyperactivity disorder: concurrent and longitudinal correlates. J Abnorm Child Psychol 2004, 32:535-550.
15. Spencer T., Heiligenstein J.H., Biederman J., et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63:1140-1147.
16. Michelson D., Faries D., Wernicke J., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108:E83. Atomoxetine ADHD Study Group.
17. Michelson D., Allen A.J., Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002, 159:1896-1901.
18. Kelsey D.K., Sumner C.R., Casat C.D., et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004, 114:e1-e8.
19. Newcorn J.H., Michelson D., Kratochvil C.J., et al. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics 2006, 118:e1701-e1706. Atomoxetine Low-Dose Study Group.
20. Michelson D., Adler L., Spencer T., et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53:112-120.
21. Adler L.A., Spencer T., Brown T.E., et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009, 29:44-50.
22. Wilens T.E., Spencer T.J., Biederman J., et al. A controlled clinical trial of burpropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001, 158:282-288.
23. Gao H, Zhao Y, Levine L, Allen A. Determining cut-points for clinically meaningful improvement: an ROC approach. Presented at: 53rd annual meeting of American Academy of Child and Adolescent Psychiatry; October 24-29, 2006; San Diego, Calif.
24. Biederman J., Faraone S.V., Spencer T., et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993, 150:1792-1798.
25. Kessler R.C., Adler L.A., Barkley R., et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005, 57:1442-1451.
26. McCarthy S., Asherson P., Coghill D., et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009, 194:273-277.
27. Strattera (atomoxetine hydrochloride) [package insert] 2008, Eli Lilly and Company, Indianapolis, Ind.
28. Brinker A., Mosholder A., Schech S.D., et al. Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. J Child Adolesc Psychopharmacol 2007, 17:328-333.